Published in Proteomics Weekly, March 7th, 2005
The SERM tamoxifen "is widely used in the treatment of estrogen receptor (ER)-expressing breast cancer," oncologists in the United States explained. "It has previously been shown that high-dose tamoxifen has cytotoxic activity against glioma cells, but whether this effect is drug-specific or represents a general property of SERMs is unknown."
In a recent study, A.M. Hui and coauthors at the National Cancer Institute found that "tamoxifen and CC-8490, a novel benzopyranone with SERM activity, induce glioma cell apoptosis in a dose- and time-dependent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.